FI951250A - Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot - Google Patents

Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot Download PDF

Info

Publication number
FI951250A
FI951250A FI951250A FI951250A FI951250A FI 951250 A FI951250 A FI 951250A FI 951250 A FI951250 A FI 951250A FI 951250 A FI951250 A FI 951250A FI 951250 A FI951250 A FI 951250A
Authority
FI
Finland
Prior art keywords
inhibitors
interleukin
pharmaceutical formulations
pharmaceutical compositions
viscosity
Prior art date
Application number
FI951250A
Other languages
English (en)
Swedish (sv)
Other versions
FI951250A0 (fi
Inventor
Benjamin K Sabados
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of FI951250A publication Critical patent/FI951250A/fi
Publication of FI951250A0 publication Critical patent/FI951250A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI951250A 1992-09-17 1995-03-16 Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot FI951250A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94700692A 1992-09-17 1992-09-17
PCT/US1993/008802 WO1994006457A1 (en) 1992-09-17 1993-09-17 Pharmaceutical formulations of interleukin-1 inhibitors

Publications (2)

Publication Number Publication Date
FI951250A true FI951250A (fi) 1995-03-16
FI951250A0 FI951250A0 (fi) 1995-03-16

Family

ID=25485348

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951250A FI951250A0 (fi) 1992-09-17 1995-03-16 Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot

Country Status (19)

Country Link
EP (1) EP0661992B1 (fi)
JP (1) JP3626755B2 (fi)
KR (1) KR950703358A (fi)
AT (1) ATE257389T1 (fi)
AU (1) AU675969B2 (fi)
CA (1) CA2141953C (fi)
CZ (1) CZ291261B6 (fi)
DE (1) DE69333378T2 (fi)
DK (1) DK0661992T3 (fi)
ES (1) ES2213744T3 (fi)
FI (1) FI951250A0 (fi)
HU (1) HU219445B (fi)
NO (1) NO321453B1 (fi)
NZ (1) NZ256328A (fi)
PL (1) PL175705B1 (fi)
PT (1) PT661992E (fi)
RO (1) RO113528B1 (fi)
RU (1) RU2126262C1 (fi)
WO (1) WO1994006457A1 (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
WO1997032572A2 (en) * 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP4610154B2 (ja) * 2002-05-30 2011-01-12 大塚製薬株式会社 注射用製剤
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
CN101918018B (zh) 2007-11-14 2012-12-05 再生医药有限公司 使用白介素-1受体拮抗剂作为骨髓保护剂的方法
US20110098267A1 (en) * 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
AU2010317842A1 (en) 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
US8853150B2 (en) 2010-07-29 2014-10-07 Eleven Biotherapeutics, Inc. Chimeric IL-1 receptor type I antagonists
WO2012078101A1 (en) * 2010-12-07 2012-06-14 Swedish Orphan Biovitrum Ab (Publ) Method for the treatment of il-1 mediated diseases
BR112013020195B1 (pt) 2011-02-11 2020-01-07 Swedish Orphan Biovitrum Ab (Publ) Composição farmacêutica livre de citrato compreendendo anakinra e uso de anakinra
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN104066439A (zh) * 2011-07-29 2014-09-24 十一生物治疗股份有限公司 纯化的蛋白质
AU2014243839B2 (en) 2013-03-13 2019-01-03 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10751426B2 (en) * 2015-10-30 2020-08-25 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416568B2 (fi) * 1972-09-29 1979-06-23
JPS537491B2 (fi) * 1972-09-30 1978-03-18
AU9106491A (en) * 1991-01-17 1992-08-27 Upjohn Company, The Method of preventing and treating insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
CZ64395A3 (en) 1995-10-18
DE69333378T2 (de) 2004-07-01
ES2213744T3 (es) 2004-09-01
CZ291261B6 (cs) 2003-01-15
DK0661992T3 (da) 2004-04-05
EP0661992B1 (en) 2004-01-07
RU2126262C1 (ru) 1999-02-20
NZ256328A (en) 1997-06-24
NO951006L (no) 1995-03-15
WO1994006457A1 (en) 1994-03-31
HU9500790D0 (en) 1995-05-29
PT661992E (pt) 2004-05-31
PL175705B1 (pl) 1999-01-29
HUT71679A (en) 1996-01-29
JPH08504755A (ja) 1996-05-21
CA2141953C (en) 2008-04-08
AU675969B2 (en) 1997-02-27
RO113528B1 (ro) 1998-08-28
FI951250A0 (fi) 1995-03-16
DE69333378D1 (de) 2004-02-12
CA2141953A1 (en) 1994-03-31
ATE257389T1 (de) 2004-01-15
EP0661992A1 (en) 1995-07-12
AU4927693A (en) 1994-04-12
NO321453B1 (no) 2006-05-15
PL308543A1 (en) 1995-08-21
JP3626755B2 (ja) 2005-03-09
NO951006D0 (no) 1995-03-15
HU219445B (hu) 2001-04-28
KR950703358A (ko) 1995-09-20

Similar Documents

Publication Publication Date Title
FI951250A (fi) Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot
RU95106996A (ru) Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидные соединения, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
SE7903186L (sv) Cerebralverksamt medel
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
RU95106823A (ru) Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
ATE245977T1 (de) Therapeutische substituierte guanidine
DE69710065T2 (de) Androsten-derivate
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
SE9201628D0 (sv) Pharmaceutical composition
EA199900876A1 (ru) Фармацевтические композиции против кашля
ATE238343T1 (de) Inhibitoren des endothelin konvertierenden enzyms
FI935777A (fi) AIDSin hoitamisessa käyttökelpoiset HIV-proteaasin inhibiittorit
IT1196307B (it) Formulazioni farmaceutiche acquose di piroxicam monoidrato
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
DE69418035D1 (de) Hiv-proteaseinhibitoren
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
MX9204815A (es) Hexahidrobenzo[f]quinolinonas y formulacion farmaceutica que las comprende.
ES2091039T3 (es) Nuevos bis-fenil-hexenos.
DK1100463T3 (da) Injicerbare formuleringer indeholdende ramoplanin
GEP19991586B (en) Pharmaceutical Formulation
RU95106624A (ru) Гидроксиэтиламиносульфонамиды, промежуточные соединения, фармацевтическая композиция, способ ингибирования ретровирусных протеаз, способ лечения ретровирусных инфекций, способ лечения спида